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In psychopathology research, endophenotypes are a subset of biomarkers that indicate genetic vulnera-
bility independent of clinical state. To date, an explicit expectation is that endophenotypes be specific to
single disorders. We evaluate this expectation considering recent advances in psychiatric genetics, recog-
nition that transdiagnostic vulnerability traits are often more useful than clinical diagnoses in psychiatric
genetics, and appreciation for etiological complexity across genetic, neural, hormonal and environmental
levels of analysis. We suggest that the disorder-specificity requirement of endophenotypes be relaxed, that
neural functions are preferable to behaviors as starting points in searches for endophenotypes, and that
future research should focus on interactive effects of multiple endophenotypes on complex psychiatric
disorders, some of which are ‘phenocopies’ with distinct etiologies.
First draft submitted: 4 January 2017; Accepted for publication: 6 June 2017; Published online: 11
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Nearly a decade ago, I (TP Beauchaine) wrote an editorial for this journal in which I summarized differences
between endophenotypes and other biomarkers [1]. It is an honor to write a sequel to that editorial following Irving
Gottesman’s recent death. Gottesman brought the endophenotype concept to psychiatry from evolutionary biology,
where John and Lewis [2] discovered that grasshopper adaptation to local environments could not be explained
by exophenotypic variation, but could be explained by endophenotypic variation – genetically induced individual
differences expressed at the microscopic rather than macroscopic level of analysis. Although this insight ran counter
to Darwin’s account of evolution by natural selection of exophenotypes, it is now clear that endophenotypes of all
kinds confer selective advantages in local environments. The sickle-cell trait protecting against malaria infection
provides one example.
Ten years ago, there was widespread optimism in the psychopathology research community that identifying
endophenotypes could lead to major breakthroughs in psychiatric genetics. Such optimism was spawned in large part
by Gottesman and Gould’s [3] now famous paper on the promise of endophenotypes. This paper, which has been cited
thousands of times, defined the endophenotype concept, explained how it could be applied in schizophrenia research
to pinpoint molecular genetic targets, and identified eye-tracking dysfunction and sensorimotor gating as likely
endophenotypes [1,3]. In a follow-up article, Gould and Gottesman [4] restricted the definition of endophenotype to
make the concept more useful for psychiatric genetics. Our objectives in writing this essay are to revisit the definition
of endophenotype, and to contextualize its current scientific utility in behavioral neuroscience given claims that
core assumptions made by those who conduct endophenotype research are mistaken [5], lingering confusion about
important distinctions between endophenotypes and other types of biomarkers, major advances in psychiatric
genetics, widespread recognition – as exemplified in the Research Domain Criteria initiative – that vulnerability
traits are often more useful than clinical diagnoses as dependent variables in psychiatric genetics research [6], and
greater appreciation for etiological complexity across genetic, neural, hormonal and environmental levels of analysis.
Discussing these points illustrates why the endophenotype concept is still promising, even though endophenotypes
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for specific psychiatric disorders remain elusive [7]. Failed/incomplete attempts to identify endophenotypes could
lead the field to prematurely abandon the concept. However, few studies conducted to date have evaluated
endophenotypes of heritable vulnerability traits (e.g., impulsivity, irritability, anhedonia) that cut across traditional
diagnostic boundaries. Refocusing endophenotype research on neurobiological mechanisms of such traits rather
than traditional diagnoses may hold promise moving forward, as discussed below [8]. Throughout this article,
we maintain a clear distinction between vulnerability traits as latent (i.e., not overtly observable) liabilities to
psychopathology, and symptoms as manifest (i.e., directly observable) signs of latent vulnerability. This is an
important distinction to maintain when discussing endophenotypes, which by definition are not captured by overt
symptoms, but are closer to pathophysiology.
Pathognomonic signs versus transdiagnostic vulnerabilities
Throughout the 20th century and up until quite recently, psychiatry and related disciplines were focused intensely
on discovering pathognomonic signs of mental illness [9]. Pathognomonic signs indicate unequivocally that a person
has a specific disorder. In medicine, these signs are fundamental to effective diagnosis and treatment. For example,
malaria parasite antigens in the bloodstream confirm that a patient is either infected, or suffered an infection in the
past. No other disease process and no other etiology is possible. If antigens are identified, antimalarial treatment
can be initiated to prevent primary or relapse infections. This simple example illustrates why pathognomonic signs
are so valuable; they are sensitive, specific, and denote a fundamental understanding of disease process, facilitating
prevention and more effective treatment.
An (often implicit) assumption of the search for pathognomonic signs in psychiatry is that different mental
disorders arise from consistent, predictable, and largely independent pathophysiologies [9,10]. As elaborated below,
this assumption undergirds the logic of the endophenotype concept, and must be met – at least to some degree – for
endophenotypes to be discovered (see ’The endophenotype concept defined’ section). Yet research conducted over
the past decade suggests that very few psychiatric disorders arise from single disease processes, and that occurrences
of highly similar neuropsychiatric conditions represent phenocopies with distinct pathogenic mechanisms (e.g., the
intellectual disabilities and ‘autisms’). Moreover, many psychiatric conditions represent extreme behavioral expres-
sions of multifactorially inherited traits for which no specific gene – and perhaps no particular combination of genes
– is necessary or sufficient for psychiatric morbidity. In rare cases, the same disorders may be influenced strongly by
highly deleterious genetic variants (e.g., 22q11.2 deletion in schizophrenia), yet that same variant may confer liabil-
ity not only to schizophrenia but also to a range of phenotypes spanning cognitive disability to affective disorder to
epilepsy. Furthermore, genetic and neural underpinnings of what have traditionally been conceptualized as distinct
disorders are known to overlap [11]. These genetic and neural processes give rise to transdiagnostic vulnerabilities
that interact complexly with other genetic liabilities and other vulnerability traits, and are therefore not specific
to current diagnostic classes [9,12–13]. Viewed in this context, and by way of example, the fact that dexamethasone
nonsuppression characterizes some but not all forms of major depression warrants continual revisitation (rather
than abandonment) of the test’s usefulness as a biomarker of important etiological subtypes of depression with very
different long-term courses [14,15]. More generally, such findings suggest that searches for new endophenotypes will
be unproductive as long as we expect them to fulfill the criterion of being pathognomonic for disease entities that
arise from heterogeneous causes and constitute, in essence, phenocopies of disparate biological processes.
The endophenotype concept defined
Gottesman and Gould described endophenotypes as ‘measurable components unseen by the unaided eye along
the pathway between disease and distal genotype’ (p. 636) [3]. They were agnostic regarding preferred levels of
analysis, stating that endophenotypes could be represented in neurophysiology, biochemistry, neurocognition, self-
report, or assorted other outcomes. Regardless of the level of analysis, to be useful endophenotypes must mark
genetic vulnerability, and be amenable to more precise measurement than overt phenotypes. Gottesman and Gould
recognized that measurement error is introduced at every level of analysis between genotypes and phenotypes, and
that many if not most phenotypes are therefore imprecise (see Figure 1).
Following from this underlying philosophy, Gould and Gottesman [4] specified the following six criteria for
endophenotypes:
 An endophenotype must segregate with illness in the general population;
 An endophenotype must be heritable;





















































Figure 1. Levels of analysis and measurement precision of genotypes, endophenotypes, and phenotypes.
Relations among genotypes, endophenotypes and phenotypes (A) and putative differences in measurement precision (B).
Endophenotypes, which can be specified at many levels of analysis including neurobiological and behavioral, fall along pathways
between (i.e., ‘bridge’) genotypes and phenotypes. A traditional assumption is that measurement precision of endophenotypes exceeds
that of phenotypes (see text). The leftmost graph of (B) depicts perfect measurement precision of a dichotomous genetic vulnerability,
distributed in equal proportions (50:50) in a sample of n = 1000. This level of precision is associated with genotyping a monogenic trait.
The middle graph depicts measurement of an endophenotype of large effect size. The right graph depicts a phenotype measured with
50% error – a situation common to ratings of observed behavior [16]. As envisioned by Gottesman and Gould [3], better measurement
precision of endophenotypes facilitates identification of genotypes.
 An endophenotype must be state independent, manifesting whether illness is present or in remission;
 An endophenotype must cosegregate with the disorder within families;
 An endophenotype must be present at a higher rate within affected families than in the general population;
 An endophenotype should be a characteristic that can be measured reliably, and specific to the illness of interest.
These criteria specify how endophenotypes differ from other biomarkers (e.g., state-dependent biochemical features,
surrogate end points, etc.) [1]. By definition, endophenotypes mark genetic vulnerability independent of clinical
state, so biomarkers that change with illness episodes do not qualify. For example, even though low levels of
brain-derived neurotrophic factor (BDNF) are observed among individuals with bipolar disorder, such findings
are restricted to acute manic episodes, and therefore change with clinical state [17]. Thus, low BDNF does not
qualify as an endophenotype and cannot be used to infer genetic liability during depressive or euthymic states. As
psychiatry progresses from exclusively syndromal toward pathophysiological diagnosis, findings such as these will
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have clinical as well as research implications. Continuing with this example, if normal BDNF levels are used to
incorrectly rule out bipolar disorder in a currently depressed individual who has yet to experience his/her first manic
episode, antidepressant treatment for unipolar depression would ensue, with possible iatrogenic effects including
increased suicide risk [18]. This example and others illustrate why endophenotypes should not be equated with
state-dependent biomarkers. One hope is that endophenotypes will eventually be used as prospective markers of
vulnerability to psychopathology, facilitating prevention [1,3].
Complications for the endophenotype concept?
The endophenotype concept has been immensely successful in affecting how psychiatrists and other psychopathol-
ogists think about gene-behavior relations, and in stimulating new research. In 2003, when Gottesman and Gould
published their now famous article [3], 38 papers referenced endophenotypes. As of 4 August, 2017, 42,985 papers
have done so. Although we cannot possibly summarize this literature, several themes present real or apparent prob-
lems for the endophenotype concept as envisioned by Gould and Gottesman. Some of these problems emerged
soon after their second paper was published, when Flint and Munafò [5] conducted a large meta-analysis to evaluate
effect sizes for putative endophenotypes of several psychiatric disorders. The authors found no evidence to support
the hypothesis that effect sizes for endophenotypes exceed those for exophenotypes (although this has traditionally
been an assumption of endophenotypes, it need not be expected when endophenotypic liabilities confer additive,
incremental and/or interactive vulnerability to disease [discussed later in this Perspective]).
More recently, a special issue of Psychophysiology was devoted to evaluating 17 putative electrophysiological
endophenotypes of schizophrenia liability among nearly 5000 twins and parents in the Minnesota Twin Family
Study, using genome-wide scans [19]. Like the schizophrenia phenotype itself, electrophysiological markers were
heritable, yet common molecular genetic variants (ascertained via genome-wide association) singly accounted for
small proportions of their heritable variance [20]. Similar findings for exophenotypes have plagued psychiatric
genetics [21], and suggest that the molecular genetic bases of schizophrenia are inordinately complex [22] – a state
of affairs that applies to most psychiatric disorders. Although some have suggested that such results undermine
the endophenotype concept altogether, any such conclusion is premature given several considerations outlined
below. Even for schizophrenia, as sample sizes have grown for molecular genetic analysis (some on the order five-
to six-times the size of the Minnesota study), it has become tenable statistically to ascertain joint influences of
numerous common variants, to identify allelic combinations that signal vulnerability to disease, and to explore
associations between candidate endophenotypes and specific profiles of polygenic risk. In addition, preliminary
studies using small samples suggest that genetic vulnerability may be manifested in certain neural functions [23].
However, state dependence of these functions remains to be determined.
Loose definitions of endophenotypes
Gottesman and Gould [3] were painstaking in their selection of putative endophenotypes, taking great care to
ensure that their six criteria (see ’The endophenotype concept defined’ section) were met. Irregularities in smooth
pursuit eye tracking, for example, which are measured by sophisticated eye-tracking equipment, are observed in
about 80% of those with schizophrenia, about 45% of their first-degree relatives, and about 10% of community
controls [3]. This 10% figure is compatible with the estimated base rate of schizophrenia liability in the general
population (genetic liability is not fully penetrant, so only a fraction of the 10% develop the disorder) [24]. These and
other findings indicate that eye-tracking dysfunction segregates with illness in the population, is heritable, is state-
independent, cosegregates with illness in pedigrees, is more common in pedigrees than in the general population,
and can be measured precisely and is specific to schizophrenia liability [1,3]. Thus, eye-tracking dysfunction meets
all six of Gould and Gottesman’s criteria. It is also worth noting that in choosing eye-tracking dysfunction and
sensorimotor gating as endophenotypes, Gottesman and Gould passed over many other biomarkers of schizophrenia
that although useful in certain contexts, did not meet their criteria.
In contrast to such precaution, many papers in the psychopathology literature treat the terms endophenotype
and biomarker interchangeably. In fact, many who study biological correlates of mental disorders refer to any and
all such correlates as endophenotypes, without considering Gould and Gottesman’s criteria [25]. Furthermore, for
most disorders, systematic evaluations of putative endophenotypes using the Gould and Gottesman’s criteria have
not been conducted. In the remainder of this article, we offer suggestions for revising the endophenotype concept,
and for conducting more systematic evaluations given advances in our understanding of psychopathology in the
past decade, particularly in the area of psychiatric genetics.
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Problems with choosing endophenotypes based on current diagnostic categories: the case of
ADHD
Several problems arise from the practice of considering all neurobiological correlates of psychopathology as en-
dophenotypes [25]. Some of these problems are illustrated in research on ADHD, for which several putative
endophenotypes have been suggested [26]. Genetic association studies consistently yield significant odds ratios for
those with ADHD versus controls on several variants that affect dopamine (DA) neurotransmission [27]. Some of
these genes are expressed heavily in the striatum [28], which is downregulated and therefore under-responsive in
anticipation of incentives among those with ADHD [28]. These deficits in striatal responding are a core neural
substrate of impulsive decision-making, a hallmark of the ADHD phenotype [29]. Collectively, such findings imply
that striatal responding to incentives might be an endophenotype of ADHD [26], particularly given a plausible
causal pathway from genetic variation → neural responding → behavior. However, when applying Gould and
Gottesman’s criteria, it is readily apparent that striatal responding to incentives does not qualify as an endopheno-
type. Although some aspects of striatal DA function are heritable [30], striatal under-responding to reward is also
observed among those with other disruptive behavior disorders, including conduct disorder, antisocial personality
disorder and substance-use disorders [12,31]. This lack of specificity might be explained away by high co-morbidities
of ADHD with other externalizing disorders, yet additional findings present more intractable problems.
Blunted striatal responding to incentives is also observed among depressed children, adolescents, and adults [32,33],
and among those who self-injure [34]. As a result, it has been advanced as an endophenotype of depression by research
groups who study mood disorders (in parallel to those who study ADHD) [35]. Currently, although low striatal
responding appears to mark premorbid risk for depression [36], which suggests state independence, it is not specific
to any syndrome (e.g., major depression) or class of disorders (e.g., disruptive behavior disorders). Although one
course of action is to reject striatal responding as an endophenotype – another is to relax disorder specificity as a
criterion for endophenotypes, and to include state-independent biomarkers that confer vulnerability to multiple
disease states for which at least some individuals share pathophysiology.
Diagnostic categories versus transdiagnostic vulnerabilities
An emerging consensus in the psychopathology research community is that complex functional interactions
among a limited number of neural and hormonal systems – far fewer in quantity than syndromes defined in the
psychiatric nomenclature – give rise to many if not most mental health conditions [6,12]. From this perspective,
endophenotypes might be more effectively reconstrued as markers of genetic liability to transdiagnostic vulnerability
traits (e.g., impulsivity, irritability, anhedonia). As Skuse noted over 15 years ago, ‘. . . a focus on traits, rather
than syndromes, is appropriate and could in due course contribute to the redefinition of traditional psychiatric
syndromes’ (p. 395) [37]. When reframed in this way, common neural correlates of psychopathology among what
have traditionally been considered as distinct disorders are no longer a nuisance in our quest for greater specificity,
but are instead opportunities to better understand common etiologies. This reformulated approach to understanding
psychopathology undergirds the Research Domain Criteria initiative [6], but has not filtered down fully into research
on endophenotypes.
Building again on the example of blunted striatal DA function, this suggests several logical next steps, including
(a) describe/demarcate boundaries of the vulnerability trait it confers; assess its heritability, as opposed to heri-
tabilities of specific disorders; and evaluate patterns of shared molecular genetic risk among traditionally defined
disorders encompassed by the trait. This approach represents a major shift in philosophy over disorder-specific
searches for endophenotypes. Instead of traditionally defined disorders (phenotypes) serving as starting points from
which we work backward to infer potential endophenotypes (then evaluate their associations with genetic liability),
an alternative is to begin with neural function (a putative endophenotype) or a ‘gene-first’ approach as a starting
point, working forward and backward to: specify common behavioral traits (phenotypes) that such neural functions
imbue, and ascertain genetic liability.
Returning to the example of midbrain DA function, a now sizable body of literature indicates that low tonic
striatal DA activity and blunted striatal DA reactivity during reward anticipation imbue an anhedonic, irritable
mood state that characterizes ADHD, other externalizing disorders, unipolar depression, and intentional self-
injury [11]. Moreover, comorbidity rates between ADHD and unipolar depression are high [38], the disorders share
molecular genetic liability [38,39], and both are characterized by present bias in decision-making (preference for
immediate overdelayed rewards) [40]. Although the heritability of anhedonia has not been evaluated in large twin
studies, irritability is moderately heritable [41].
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Figure 2. Etiological complexity of ADHD and unipolar depression.
Blunted striatal responding to incentives (left panel, top) arises from aggregation of and complex interactions among normal allelic
variation, heritable CNVs, de novo mutations, epigenetic factors, environmental risk exposures and neurohormonal influences. Very few
of these are necessary or sufficient to produce the resulting subcortical endophenotype. Low striatal responding predisposes to trait
anhedonia/irritability (a psychological state), producing a behavioral bias to reward seeking, which can temporarily upregulate aversive
mood. Importantly, this behavioral bias can be moderated by other subcortical systems, including the amygdala and its interconnections
(left panel, bottom). Strong amygdalar response to threat (a moderating subcortical endophenotype) predisposes to trait anxiety (a
largely independent psychological state), which moderates trait anhedonia to produce a behavioral bias to immobilization. In most cases,
these behavioral biases are insufficient to eventuate in psychopathology in the absence of prefrontal cortex dysfunction (a potentiating
cortical endophenotype). Poor prefrontal regulation of subcortically generated emotions is observed in almost all forms of
psychopathology (see text). For the sake of clarity, specific frontal structures that regulate subcortical systems (dorsolateral prefrontal
cortex, ventromedial prefrontal cortex, orbitofrontal cortex, anterior cingulate cortex), and interconnections among subcortical systems
(extended amygdala, bed nucleus of the stria terminalis) are omitted.
Collectively, these findings suggest that phenotypically dissimilar disorders share a common neural vulnerability
– expressed psychologically as trait anhedonia and irritability. This state of affairs is depicted in Figure 2. Low
midbrain DA activity and reactivity to incentives – neural vulnerabilities to both ADHD and unipolar depression [11]
– emerge from interactions among numerous etiological inputs including normal allelic variation [42–44], heritable
CNVs [45,46], de novo mutations [47], epigenetic changes in receptor function [48], neurotoxic environmental risk
exposures [48] and neurohormonal influences [49,50], among other factors [12]. These influences aggregate and
interact to induce an anhedonic and irritable mood state that confers vulnerability to both externalizing disorders
and unipolar depression. Blunted striatal responding to incentives is therefore not an endophenotype of any specific
disorder. Rather, it is an etiologically complex transdiagnostic neural vulnerability. This raises the obvious question
of why two affected individuals can display such different behavioral outcomes.
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Etiological complexity I: moderating effects of other subcortical systems
Externalizing disorders are distinguished from unipolar depression by moderating effects of other subcortical and
cortical networks on the midbrain DA system. These moderating influences, along with nonshared environmental
influences, can shape trait vulnerability into different behavioral manifestations [12,51]. Among the most important
of these moderators is amygdalar function. Unipolar depression is characterized by volumetric abnormalities in the
amygdala [52], and by amygdalar hyper-reactivity to threat [53]. In contrast, externalizing disorders are characterized
by amygdalar hyporeactivity to similar stimuli [54]. As illustrated in Figure 2, individual differences in amygdalar
responding (and in its functional neuroanatomical connections) interact with individual differences in striatal
function [55] to moderate behavioral expression of anhedonia/irritability. Thus, anhedonia and irritability motivate
reward-seeking behavior primarily among those with low amygdalar responding to threat because they lack anxiety
and fear [56]. For these individuals, appetitive behaviors upregulate midbrain DA levels, providing temporary
relief from their chronically aversive mood state [11]. In contrast, those who are hyper-responsive to threat engage
primarily in passive avoidance rather than reward-seeking because they experience anxiety and fear, which inhibit
appetitive behaviors. Like striatal DA responding, amygdalar reactivity to threat is heritable, and has its own set of
intricate and interactive causal influences (see Figure 2), which cannot be reviewed here given space constraints.
Thus, two subcortically founded, heritable traits (anhedonia/irritability vs threat sensitivity), imbued by different
neurobiological mechanisms, interact to affect psychological adjustment and behavioral expressions of vulnerability.
Several important points follow from this discussion. First, heritable individual differences in neurobiological
functions interact with one another, which can ‘shift’ behavioral distributions of each trait, thereby obscuring
any 1:1 correspondence between genes and behavior [13]. Thus, we should be circumspect about using behaviors
as starting points to infer endophenotypes (discussed earlier in this Perspective). Second, etiology is inordinately
complex [12,31,57]. Etiological complexities that were either unrecognized or only nascently recognized when Gould
and Gottesman defined endophenotypes are now known to operate in many forms of psychopathology. As noted
above, for example, much greater appreciation for multifactorial inheritance – whereby few if any genes are
necessary or sufficient for psychiatric morbidity – has emerged. Furthermore, rare copy number variants, many
of which are not inherited, play a significant role in almost all major classes of psychopathology [58], contributing
further to genetic complexity. Third, epigenetic changes in gene expression are common, and can affect neural
functions that subserve motivation, mood regulation, and social affiliation [59]. These neural systems are interactive
and interdependent, which further obfuscates any linear trajectories across genetic → neural → behavioral levels
of analysis. Finally, nonepigenetic environmentally induced influences on neural responding can affect behavior,
producing ‘phenotypes’ that are indistinguishable from those that are genetically mediated. Teratogen exposure,
hypoxic events, and use of strong stimulants all downregulate striatal DA responding, with behavioral consequences
that are indistinguishable from the heritable ADHD phenotype [48].
Etiological complexity II: potentiating effects of cortical systems & general liability to
psychopathology
Given the above discussion, it is important to note that subcortical neural function rarely determines psychopathol-
ogy, except in extreme cases such as focal lesions [60]. Many individuals who suffer from no psychiatric condition
exhibit below normal striatal responding to incentives, and ordinary variation in such responding gives rise to
individual differences in personality [28]. Many people who are high on trait anxiety also function well in their
day-to-day lives. Thus, subcortical neural systems are insufficient to explain the functional impairment that char-
acterizes most forms of psychopathology [9,61]. Rather, psychopathology is most likely when strong, subcortically
generated emotions are not regulated effectively by functional subdivisions of the prefrontal cortex [51].
Effortful regulation of appetitive emotions, such as wanting, is exerted through dorsolateral prefrontal and
orbitofrontal inhibition of striatal activity and reactivity, whereas effortful regulation of aversive emotions, such as
anxiety and fear, is exerted through lateral prefrontal inhibition of amygdalar activity and reactivity [62,63]. Those
with externalizing disorders exhibit diminished functional connectivity between striatal and frontal structures [64],
whereas depressed and anxious individuals exhibit altered functional connectivity between the amygdala and the
ventrolateral PFC, the ventromedial PFC, and the anterior cingulate [65]. In addition, poor functional connectivity
between the amygdala and the orbitofrontal cortex, and poor top-down control of the amygdala by the medial PFC,
are implicated in emotional lability [66]. Thus, failures in prefrontal regulation of subcortical structures involved in
approach- and avoidance-related affect are observed in both externalizing and internalizing disorders.
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The two right panels of Figure 2 depict the potentiating role of poor emotion regulation and executive function
on psychopathological outcomes. When the subcortical substrates of reward-seeking and immobilization are met
with poor top-down cortical regulation, psychopathology becomes likely. Thus, gradations from normal personality
variation to psychopathology, depicted in green, are determined by interactions among subcortical structures that
generate emotion, and cortical structures that regulate emotion [67].
Etiological complexity III: underexplored dimensions of general psychopathology
Historically, intellectual disabilities, autism and temperamental liabilities to personality disorder have been split off
from many studies of psychopathology on the basis of preconceived notions that their origins are distinct from those
that confer liability to common (formerly Axis I) DSM-defined disorders. The fact that comorbidities between the
former and latter types of disorder are the rule rather than the exception, and that intellectual disability, autism, and
personality disorder represent pathological tails along continuous distributions of trait vulnerabilities (i.e., general
cognition, reciprocal social behavior, cooperativeness, respectively) in the population highlights the importance of
accounting for effects of variation in these traits in any study relating phenotype → endophenotype → neural
mechanism → gene in human populations. These ‘modifiers’ are rarely considered and often excluded in highly
selective research designs. The example of autism is instructive because it reflects effects of an endophenotypic
influence that bears a formidable 1:1 relationship to a highly heterogeneous disease state (autism spectrum disorder;
ASD) [68], and simultaneously, when present, accentuates severity of any co-morbid psychopathologies [69].
When standardized methods for quantitative assessment of ASD symptoms and traits are applied to the general
population, the unequivocal result from a host of studies, implementing numerous measurement instruments, is
that characteristic traits and features are distributed continuously – not bimodally – in nature [70]. Remarkably, these
traits (deficits in reciprocal social behavior, impairment in social communication, repetitive behavior, restriction in
range of interests) are as highly correlated in the general population as they are (by definition) among individuals
with clinical ASD syndromes; thus exhibiting a unitary factor structure in the general population. Furthermore,
when measurements of subclinical autistic traits are implemented in studies of families affected by ASD, they
aggregate among first-degree relatives with a frequency and order of magnitude higher than observed in the general
population [71,72]. This is not the case in families affected by other psychiatric conditions, however, when present,
subclinical autistic traits exacerbate the severity of nearly any psychiatric condition with which they co-occur [68].
Finally, in very large genetic–epidemiologic studies, genetic susceptibilities to these subclinical syndromes exhibit
near-complete overlap with genetic underpinnings of the clinical-level syndromes [71], suggesting strongly that
continuous distributions observed in nature relate to quantitative accumulation of causal liability. Collectively, such
findings fulfill criteria to establish that this trait cluster an autism endophenotype.
It is important to note that in the same way that height influences weight, neurodevelopmental characteristics
of variation in general cognition, reciprocal social behavior and temperament can influence behavior and psy-
chopathology such that specification of the role of any single endophenotype within an individual will ultimately
require established maps of expectable relations between variables (analogous to the height vs weight norms for
males and females used in pediatric practice) to ascertain relative contributions of multiple causal factors to a given
neuropsychiatric syndrome [73]. Moreover, when considering the role of inherited variation in neurodevelopmental
traits on psychopathology, it is important to note that the recent explosion in genetic studies of neurodevelopmental
disorders (made possible by steady reductions in costs of genotyping) have greatly expanded our understanding of
the diversity of genetic influences on development and behavior. As noted above, causal heritable influences on
neurodevelopmental outcomes can be common or rare, inherited or de novo (germline), specific to a disease (Rett
Syndrome) or largely nonspecific (many chromosomal rearrangements). It is likely that this full diversity of types
of genetic influence is operative in the development of psychopathology, and that diversity constitutes a confound
when biomarker research is either not genetically informative or predicated on only a singular model of inheritance
(e.g., additive genetic influence in twin studies).
Conclusion
Etiological complexity is the rule rather than the exception for major psychiatric disorders. Overt behaviors
(i.e., phenotypes), including psychopathology, are affected by myriad interactive genetic factors (both heritable
and nonheritable), interdependent neural systems that alter one another’s functional outputs, and environmental
insults that affect neural function. These influences bear complex relations to measured genetic liability, formidable
as the sum total of heritable influences may be. Thus, behaviors may only occasionally be the best starting points
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for identifying endophenotypes. In fact, using the word phenotype to refer to behavioral syndromes can be
misleading because it promotes anachronistic assumptions about 1:1 gene-behavior relations that do not exist for
multifactorially inherited traits.
Future perspective: implications for the endophenotype concept
Most psychiatric disorders do not represent single disease entities, and single disease processes cut across psychiatric
boundaries. This does not mean we should retire the endophenotype concept. Rather, endophenotypes may be
useful in future research, provided we recognize the transdiagnostic nature of genetic and neural vulnerabilities,
and that we evaluate interactive roles of genetic liabilities and neural systems in affecting behavior. Main effects
models of psychopathology have probably run their course [12], at least until such time as more biologically
tractable parcellations of major psychopathologies are established. Endophenotypes should be sought that map
onto genetically influenced neural functions rather than specific psychiatric disorders, and interactions among
multiple endophenotypes and functional behavioral outcomes should be evaluated. To accomplish these objectives,
effective collaborations among researchers who study different disorders, such as ADHD and unipolar depression
(see ’Discussion’ section earlier), will be required. At present, these literatures are largely uninformed by one
another [11]. Finally, the expectation that any single etiological model should explain a preponderance of variance
in a neuropsychiatric outcome should neither dominate the discovery process nor result in dismissal of important
leads that relate to subsets of individuals affected by what are now construed as single conditions. Endophenotypes
that mark heritable vulnerability may only capture a subset of those who exhibit similarly disordered behavior.
This does not represent failure; rather, it indicates that more work lies ahead in our quest to uncover the daunting
complexity of psychopathology.
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Executive summary
Endophenotypes are a subset of biomarkers that, by definition, lie closer to genetic liability than exophenotypes
 Identified originally in evolutionary biology [2].
 Introduced to psychiatry by Gottesman and Gould in research on schizophrenia [3,4].
According to their current definition, endophenotypes mark genetic liability to specific psychiatric disorders,
independent of clinical state. Endophenotypes must:
 Segregate with illness in the general population.
 Be heritable.
 Be state independent, manifesting whether illness is present or in remission.
 Cosegregate with the disorder within families.
 Be present at higher rates within affected families than in the general population.
 Be characteristics that can be measured reliably, and specific to the illness of interest.
Since these criteria were published, problems have emerged for the disorder-specificity criterion
 Most psychiatric disorders are etiologically complex, including influences of normal allelic variation, heritable
CNVs, de novo mutations, epigenetic changes in receptor function and neurohormonal influences, among others.
 Few of these are necessary or sufficient to eventuate in psychopathology.
 Transdiagnostic vulnerability traits are often more useful than clinical diagnoses as dependent variables in
psychiatric genetics research.
 Vulnerabilities to psychopathology interact with one another and with other behavioral traits
(e.g., temperament, personality) to obscure 1:1 correspondences between genetic liability and behavior.
 Many apparently similar cases of psychopathology represent ‘phenocopies’ with distinct etiologies.
Several recommendations would preserve the utility of the endophenotype concept moving forward
 The disorder-specificity requirement should in most cases be relaxed.
 Endophenotypes that mark vulnerability to multiple disorders can still be useful.
 Neural functions are preferable to behaviors as starting points in searches for endophenotypes.
 Future research should focus on interactive effects of multiple endophenotypes on complex psychiatric disorders.
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